Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

BCLI Brainstorm Cell Therapeutics Inc

Price (delayed)

$1.12

Market cap

$8.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.07

Enterprise value

$9.02M

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of ...

Highlights
The EPS has surged by 57% year-on-year and by 10% since the previous quarter
BCLI's quick ratio is up by 33% YoY
The equity has contracted by 34% YoY but it has grown by 4% from the previous quarter
BCLI's debt has soared by 74% from the previous quarter and by 58% YoY

Key stats

What are the main financial stats of BCLI
Market
Shares outstanding
7.94M
Market cap
$8.89M
Enterprise value
$9.02M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$12.31M
Net income
-$11.09M
EBIT
-$10.97M
EBITDA
-$10.74M
Free cash flow
-$7.66M
Per share
EPS
-$2.07
EPS diluted
-$2.07
Free cash flow per share
-$1.21
Book value per share
-$1.14
Revenue per share
$0
TBVPS
$0.56
Balance sheet
Total assets
$3.57M
Total liabilities
$11.03M
Debt
$1.77M
Equity
-$7.46M
Working capital
-$8.57M
Liquidity
Debt to equity
-0.24
Current ratio
0.21
Quick ratio
0.16
Net debt/EBITDA
-0.01
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-338.2%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCLI stock price

How has the Brainstorm Cell Therapeutics stock price performed over time
Intraday
5.66%
1 week
0.9%
1 month
3.23%
1 year
-85.88%
YTD
-50.66%
QTD
-11.11%

Financial performance

How have Brainstorm Cell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.31M
Net income
-$11.09M
Gross margin
N/A
Net margin
N/A

BCLI financials

Brainstorm Cell Therapeutics's operating income has increased by 34% YoY but it has decreased by 5% QoQ
The net income has increased by 29% YoY and by 4.6% QoQ

Price vs fundamentals

How does BCLI's price correlate with its fundamentals

BCLI Price vs fundamentals

BCLI Earnings waterfall

BCLI Price vs fair value

Growth

What is Brainstorm Cell Therapeutics's growth rate over time

BCLI growth chart

Valuation

What is Brainstorm Cell Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A

Valuation vs average

Price to earnings (P/E)

The EPS has surged by 57% year-on-year and by 10% since the previous quarter

Price to book (P/B)

The equity has contracted by 34% YoY but it has grown by 4% from the previous quarter

Price to sales (P/S)

Efficiency

How efficient is Brainstorm Cell Therapeutics business performance
The return on assets has increased by 6% since the previous quarter but it has declined by 3.3% year-on-year

Dividends

What is BCLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCLI.

Financial health

How did Brainstorm Cell Therapeutics financials performed over time

Assets vs liabilities

Brainstorm Cell Therapeutics's total assets is 68% less than its total liabilities
Brainstorm Cell Therapeutics's total assets has soared by 95% from the previous quarter and by 7% YoY
BCLI's quick ratio is up by 33% YoY

Debt vs equity

BCLI's debt is 124% more than its equity
The company's debt to equity has shrunk by 85% QoQ and by 20% YoY
BCLI's debt has soared by 74% from the previous quarter and by 58% YoY

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.